Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids.

Dominik Wenisch, Slavica Ždravac, Michael A Jakupec, Franz Jirsa, Bernhard K Keppler

Abstract read

In one paragraph

Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dominik WenischInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0001-5305-2048

Slavica ŽdravacInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria.

Michael A JakupecInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria. michael.jakupec@univie.ac.at.ORCID http://orcid.org/0000-0001-7945-1426

Franz JirsaInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-4926-3261

Bernhard K KepplerInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0003-0877-1822

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BOLD-100, a ruthenium(III) prodrug also known as KP1339, is currently under clinical investigation for its suitability as a co-therapeutic anticancer drug. Unlike platinum-based chemotherapeutics, it has unique non-DNA targets, mainly GRP78, an enzyme responsible for signaling related to protein folding in the ER. Inhibition of this key mediator of the "unfolded protein response" may lead to cell death eventually. The purpose of this study was to assess in vitro the impact of BOLD-100 combinations with oxaliplatin, 5-FU, cisplatin or SN38 in multicellular tumor spheroids (MCTSs) compared to single-drug treatments. Gastric (MKN45, NCI-N87) and colorectal cancer (HCT116, HT29) cell lines were chosen, corresponding to the clinical trial in which patients with tumors of these origins are being treated. Biological effects investigated in this study include cytotoxic activity, synergism/antagonism based on Chou and Talalay's algorithm, formation of reactive oxygen species (ROS) and induction of apoptosis and necrosis. Cytotoxicity tests showed vastly different chemosensitivities in MCTSs of the same tumor origin. In both tumor entities, partially synergistic effects were revealed when BOLD-100 was combined with the drugs mentioned above. The DCFH-DA assay suggested consistent increases of ROS levels after treatment with oxaliplatin and, with restrictions, its combination with BOLD-100. Apoptosis and necrosis were induced in the spheroid models by single-drug and combined treatment, with no hints at antagonism in the combination settings. In conclusion, these findings emphasize the potential of BOLD-100 for combination therapy of gastric and colorectal cancers.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsGastrointestinal NeoplasmsOrganometallic CompoundsSpheroids, CellularStomach NeoplasmsAntineoplastic AgentsApoptosisCamptothecinCell Line, TumorCisplatinDrug SynergismEndoplasmic Reticulum Chaperone BiPFluorouracilHCT116 CellsHT29 CellsAntineoplastic AgentsCamptothecinCisplatinEndoplasmic Reticulum Chaperone BiPFluorouracilHSPA5 protein, humanIrinotecanKP 1339Organometallic CompoundsOxaliplatinProdrugsReactive Oxygen SpeciesColon cancerCombination therapyGastric cancerIn vitro studiesMulticellular tumor spheroidsRuthenium drug

Identifiers

PMID42171754

DOI10.1007/s00280-026-04902-z

PMCPMC13197383

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.